A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors

Jason D. Lickliter, Hui Kong Gan, Tarek Meniawy, Jason Yang, Lai Wang, Lusong Luo, Ni Lu, Michael Millward

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

6 Citations (Web of Science)

Original language	English
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	34
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2016.34.15_suppl.e17049
Publication status	Published - 20 May 2016
Event	52nd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 3 Jun 2016 → 7 Jun 2016

Access to Document

@article{9ddf764efea24098963fb7c03d9fc105,

title = "A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors",

author = "Lickliter, {Jason D.} and Gan, {Hui Kong} and Tarek Meniawy and Jason Yang and Lai Wang and Lusong Luo and Ni Lu and Michael Millward",

year = "2016",

month = may,

day = "20",

doi = "10.1200/JCO.2016.34.15_suppl.e17049",

language = "English",

volume = "34",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

note = "52nd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 03-06-2016 Through 07-06-2016",

}

TY - JOUR

T1 - A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors

AU - Lickliter, Jason D.

AU - Gan, Hui Kong

AU - Meniawy, Tarek

AU - Yang, Jason

AU - Wang, Lai

AU - Luo, Lusong

AU - Lu, Ni

AU - Millward, Michael

PY - 2016/5/20

Y1 - 2016/5/20

U2 - 10.1200/JCO.2016.34.15_suppl.e17049

DO - 10.1200/JCO.2016.34.15_suppl.e17049

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 34

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

T2 - 52nd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 3 June 2016 through 7 June 2016

ER -